B7-H3 (CD276), which is highly and stably expressed in prostate cancer, represents a promising alternative theranostic target.<h4>Methods</h4>A B7-H3 targeted antibody-drug conjugate (ADC) was radiolabeled with [<sup>89</sup>Zr]Zr- for immunoPET imaging and [<sup>177</sup>Lu]Lu for radionuclide therapy. This evidence concerns the gene CD276 and prostate cancer.